Evidence map›Paper›PMID 41552861›Full record

ArticleBiotechnology progress

Development of a co-culture of Ureibacillus thermosphaericus and Cupriavidus taiwanensis for inhibitors removal from hemicellulose prehydrolysate.

Mariem Theiri, Mariya Marinova, Hassan Chadjaa, Mario Jolicoeur

Abstract read
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mariem TheiriResearch Laboratory in Applied Metabolic Engineering, Department of Chemical Engineering, Polytechnique Montréal, J.-A.-Bombardier Pavilion, Montréal, Quebec, Canada.ORCID 0000-0002-1930-8529
Mariya MarinovaDepartment of Chemistry and Chemical Engineering, Royal Military College of Canada, Kingston, Ontario, Canada.
Hassan ChadjaaIndustrial Bioprocesses, Centre National en Électrochimie et en Technologies Environnementales, Shawinigan, Quebec, Canada.
Mario JolicoeurResearch Laboratory in Applied Metabolic Engineering, Department of Chemical Engineering, Polytechnique Montréal, J.-A.-Bombardier Pavilion, Montréal, Quebec, Canada.

Funding

Natural Sciences and Engineering Research Council of Canada (NSERC) 437803-12NSERC Discovery Grant 380070-08NSERC Industrial Research Chair for Colleges in Bioprocess and Fermentation Technology
6 · The paper itself

Abstract

For biofuels production, hemicellulose pre-hydrolysate is considered an attractive feedstock rich in fermentable sugars. The lignocellulosic biomass comprises, along with sugars, several inhibitors that can hamper its efficient conversion. In this work, mixed cultures of Ureibacillus thermosphaericus and Cupriavidus taiwanensis were used for the first time to detoxify the pre-hydrolysate. The nutrient source was first optimized in synthetic media with mono-cultures to detoxify phenolic compounds, and a medium containing inorganic salts was selected. Afterwards, the efficiency of phenolic degradation was compared in a single-compound solution and in a mixture. The simultaneous co-culture showed the highest degradation efficiency (90% at 2.8 g/L of phenolic compounds). Finally, the detoxification of a raw pre-hydrolysate was conducted, and a maximum degradation of 14% of the phenolics was obtained using sequential inoculation of Ureibacillus thermosphaericus followed by Cupriavidus taiwanensis addition.

Indexed as

CupriavidusPolysaccharidesCoculture TechniquesHydrolysisPhenolshemicellulosePhenolsPolysaccharidesco‐culturedetoxificationphenolic compoundspre‐hydrolysatesynthetic media

Identifiers

PMID41552861
PMCPMC13055127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.